McLean C S, Ni Challanáin D, Duncan I, Boursnell M E, Jennings R, Inglis S C
Cantab Pharmaceuticals Research Ltd, Cambridge, UK.
Vaccine. 1996 Jul;14(10):987-92. doi: 10.1016/0264-410x(95)00259-4.
The vaccine potential of a genetically disabled Herpes Simplex Virus Type 1 virus (DISC HSV-1) was investigated in the guinea pig model of intravaginal (i.vag.) HSV-2 infection. Three mucosal vaccination routes, i.vag., intranasal (i.n.) and oral, were compared for their ability to protect guinea pigs from challenge with wild-type HSV-2. Each was effective, particularly the i.n. route, which almost completely abolished primary disease. This was accompanied by significantly lower challenge virus titres in vaginal swabs collected from the vaccinated animals. In all cases, vaccination with the inactivated virus preparation provided substantially less protection from disease than the live DISC HSV-1 by the equivalent route. Antibody levels in serum and vaginal washes were measured both after vaccination and challenge by ELISA and neutralization tests. The highest titres were observed following administration of the DISC HSV-1 vaccine by the i.n. route. Significant increases in IgA and IgG in vaginal wash fluids were also found in these vaccinated animals.
在单纯疱疹病毒2型（HSV - 2）阴道内感染的豚鼠模型中，研究了基因失活的1型单纯疱疹病毒（DISC HSV - 1）的疫苗潜力。比较了三种黏膜接种途径，即阴道内、鼻内和口服，观察它们保护豚鼠免受野生型HSV - 2攻击的能力。每种途径都有效，特别是鼻内途径，几乎完全消除了原发性疾病。这伴随着从接种动物采集的阴道拭子中攻击病毒滴度显著降低。在所有情况下，与通过等效途径使用活的DISC HSV - 1相比，用灭活病毒制剂接种提供的疾病保护要少得多。通过ELISA和中和试验在接种和攻击后测量血清和阴道洗液中的抗体水平。通过鼻内途径施用DISC HSV - 1疫苗后观察到最高滴度。在这些接种动物的阴道洗液中也发现IgA和IgG显著增加。
